RT Journal Article
T1 T cell–mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19.
A1 Fernández Ruiz, Mario
A1 Olea, B.
A1 Almendro-Vázquez, P.
A1 Giménez, E.
A1 Marcacuzco Quinto, Alberto Alejandro
A1 San Juan Garrido, Rafael
A1 Justo Alonso, Iago
A1 Calvo Pulido, Jorge
A1 García-Sesma Pérez-Fuentes, Álvaro
A1 Manrique Municio, Alejandro
A1 Caso Maestro, Óscar
A1 Cambra Molero, Félix
A1 Talayero, P.
A1 López Medrano, Francisco
A1 Remigia, M.J.
A1 Ruiz-Merlo, T.
A1 Parra, P.
A1 Paz Artal, Estela Natividad
A1 Jiménez Romero, Luis Carlos
A1 Loinaz Segurola, Carmelo
A1 Navarro, D.
A1 Laguna Goya, R.
A1 Aguado García, José María
AB Whether immunosuppression impairs severe acute respiratory syndrome coronavirus 2-specific T cell–mediated immunity (SARS-CoV-2-CMI) after liver transplantation (LT) remains unknown. We included 31 LT recipients in whom SARS-CoV-2-CMI was assessed by intracellular cytokine staining (ICS) and interferon (IFN)-γ FluoroSpot assay after a median of 103 days from COVID-19 diagnosis. Serum SARS-CoV-2 IgG antibodies were measured by ELISA. A control group of nontransplant immunocompetent patients were matched (1:1 ratio) by age and time from diagnosis. Post-transplant SARS-CoV-2-CMI was detected by ICS in 90.3% (28/31) of recipients, with higher proportions for IFN-γ-producing CD4+ than CD8+ responses (93.5% versus 83.9%). Positive spike-specific and nucleoprotein-specific responses were found by FluoroSpot in 86.7% (26/30) of recipients each, whereas membrane protein-specific response was present in 83.3% (25/30). An inverse correlation was observed between the number of spike-specific IFN-γ-producing SFUs and time from diagnosis (Spearman's rho: −0.418; p value =.024). Two recipients (6.5%) failed to mount either T cell–mediated or IgG responses. There were no significant differences between LT recipients and nontransplant patients in the magnitude of responses by FluoroSpot to any of the antigens. Most LT recipients mount detectable—but declining over time—SARS-CoV-2-CMI after a median of 3 months from COVID-19, with no meaningful differences with immunocompetent patients.
PB Elsevier
YR 2021
FD 2021-05-30
LK https://hdl.handle.net/20.500.14352/129813
UL https://hdl.handle.net/20.500.14352/129813
LA eng
NO Fernández-Ruiz, Mario, et al. «T Cell–Mediated Response to SARS-CoV-2 in Liver Transplant Recipients with Prior COVID-19». American Journal of Transplantation, vol. 21, n.o 8, agosto de 2021, pp. 2785-94.  https://doi.org/10.1111/ajt.16708.
DS Docta Complutense
RD 12 ene 2026